Retevmo® (selpercatinib) capsules for RET‑positive cancers

What Retevmo® Is and How It Works

Retevmo (selpercatinib) is a targeted cancer drug that blocks abnormal RET signaling. It treats metastatic or advanced RET fusion–positive non‑small cell lung cancer, RET‑mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer. Capsules come in 40 mg and 80 mg strengths. Many patients compare retevmo price and plan for retevmo without insurance expenses when starting therapy.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing. We offer brand and generic medicines at Canadian prices and also carry OTC health products. Ordering is available online (and by phone where applicable). Customer-service chat is available during posted office hours.

We source medicines through licensed, vetted partner pharmacies worldwide to provide authentic brand products, broad selection, and affordable pricing.

Retevmo is an oral tyrosine kinase inhibitor that targets RET alterations. By inhibiting RET, it can slow tumor growth and shrink RET‑driven tumors. It is taken twice daily. It can be taken with or without food, but avoid grapefruit. Acid‑reducing agents may affect exposure; timing adjustments are often used with proton pump inhibitors, H2 blockers, and antacids.

The medicine is manufactured by Eli Lilly and Company. Regulatory milestones include FDA approval and EMA authorizations; prescribers often consult the retevmo prescribing information and the retevmo USPI for detailed dosing and safety data.

Dosage and Usage

• Typical adult dosing is based on body weight: 120 mg twice daily if under 50 kg, or 160 mg twice daily if 50 kg or more.
• Swallow capsules whole with water. Do not crush, chew, or open them.
• With or without food is acceptable, but avoid grapefruit and grapefruit juice.
• If taking a proton pump inhibitor, take Retevmo with food. For H2 blockers, take Retevmo 2 hours before or 10 hours after. For antacids, separate by at least 2 hours before or after.
• If a dose is missed and it is more than 6 hours until the next dose, take it as soon as remembered. If within 6 hours of the next dose, skip the missed dose.
• If vomiting occurs after a dose, do not take an extra dose. Resume the next scheduled dose.
• Prescribers may reduce, hold, or stop the dose for side effects such as liver enzyme elevations, hypertension, or QT prolongation.
• Review all medicines and supplements. Strong CYP3A inhibitors/inducers, P‑gp substrates, and QT‑prolonging agents may require changes.

• Store capsules at 20–25 °C (68–77 °F); short excursions 15–30 °C (59–86 °F) are acceptable.
• Keep in the original, tightly closed container to protect from moisture. Do not store in a bathroom.
• For travel, carry the medication in hand luggage with the Rx label. Keep away from heat, direct sun, and freezing.
• If a weekly pill organizer is used, keep a desiccant nearby and avoid humid areas.
• Do not use past the labeled expiry date.

Benefits and Savings

Retevmo offers precision therapy for patients with RET alterations. Many see durable responses and improved symptom control. Oral dosing avoids infusion visits and can simplify daily routines. The medicine is available in 40 mg and 80 mg strengths to support dose adjustments during treatment.

Ordering from Canada can lower the retevmo cost. Typical savings vs US retail pricing are about 60–80%. Patients paying retevmo without insurance often compare retevmo cash price and retevmo out of pocket options across strengths and quantities. Multi‑month supplies or retevmo bulk promotions can reduce the per‑month cost, and you can set simple reorder reminders in your account.

For occasional offers, see our current retevmo coupon.

Side Effects and Safety

• Common: dry mouth, diarrhea or constipation, nausea, abdominal pain, fatigue, headache.
• Laboratory changes: increased ALT/AST, increased creatinine, electrolyte changes.
• Cardiovascular: hypertension, edema.
• Skin: rash, pruritus.
• Respiratory: cough.
• Others: mouth sores, joint or muscle pain.

Serious risks can include liver injury, QT prolongation, significant hypertension, bleeding, interstitial lung disease/pneumonitis, and hypersensitivity reactions. Risk of harm to an unborn baby is known; effective contraception is recommended during treatment and after the last dose as directed. This medicine is not a glucose‑lowering drug; hypoglycemia warnings apply when combining diabetes therapies such as insulin or sulfonylureas, not Retevmo.

Onset Time

Some patients experience symptom relief within weeks as therapy begins. Objective responses on imaging are often assessed at 8–12 weeks, with further changes over subsequent months as dosing stabilizes. Blood pressure and liver tests may change earlier and are monitored during the first weeks. Durability varies by indication and individual factors.

Compare With Alternatives

Gavreto (pralsetinib) is another selective RET inhibitor used for RET‑altered cancers. Dosing schedules and side‑effect profiles differ, and choice depends on prior therapies, comorbidities, and drug interactions.

Multikinase inhibitors such as vandetanib and cabozantinib have roles in medullary thyroid cancer when RET‑selective therapy is not suitable or after progression. They carry different cardiovascular and dermatologic risks and often require careful monitoring.

Immunotherapy and other targeted agents are used in broader oncology care for different tumor drivers. For example, Bavencio® (avelumab) is an immune checkpoint inhibitor for select cancers, and targeted oral therapies such as Xospata® treat specific mutations in blood cancers. These are not substitutes for RET‑directed therapy but illustrate available options in other settings.

Combination Therapy

• Retevmo is commonly used as monotherapy for RET‑altered tumors.
• Supportive medicines (antiemetics, antihypertensives) may be used to manage symptoms and blood pressure.
• Review acid‑reducing therapies and CYP3A modulators; timing or dose adjustments of Retevmo may be required.
• No dose adjustments for hypoglycemia are expected, since selpercatinib is not a glucose‑lowering drug.

Patient Suitability and Cost-Saving Tips

Candidates include adults and eligible adolescents with confirmed RET fusion–positive non‑small cell lung cancer, RET‑mutant medullary thyroid cancer, or RET fusion–positive thyroid cancer who need systemic therapy. Tumor testing guides selection. Those with uncontrolled hypertension, significant QT prolongation, or active interstitial lung disease need careful evaluation before starting.

Use may be limited or adjusted with liver impairment, serious bleeding risk, or strong CYP3A drug interactions. Avoid grapefruit. Pregnancy and breastfeeding are not recommended during treatment. Discuss contraception and fertility plans with a clinician.

To manage expenses, compare retevmo price by strength and quantity. Consider 2–3 month supplies to lower monthly costs. Reorder reminders help you stay on schedule. If managing retevmo no insurance costs, ask your prescriber about manufacturer retevmo patient assistance program pathways that may be available separately from pharmacy pricing.

Authoritative Sources

FDA Prescribing Information (USPI) for Retevmo

Eli Lilly Retevmo overview

Health Canada Drug Product Database: Selpercatinib

Order Retevmo® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This page is educational and does not replace advice from your healthcare professional. Always follow your prescriber’s directions and the patient information that comes with your medication.